Tag: Comfortear Lacrisolve
Ophthalmic Pharmaceuticals Company Paragon BioTeck Receives CE Mark Approval on Comfortear Lacrisolve Absorbable Punctum Plug
PORTLAND, Ore. /eNewsChannels/ -- NEWS: Paragon BioTeck, Inc., a privately held biopharmaceutical and medical device company specializing in the development of ophthalmic pharmaceuticals, devices and therapies, announced today that it has received CE mark approval for the recently FDA cleared Comfortear Lacrisolve Absorbable Punctum Plug. CE mark approval is recognized and associated with safety and performance in multiple countries.
Paragon BioTeck, Inc. ormally launching its corporate citizenship initiative coined, Paragon Gives
PORTLAND, Ore. /eNewsChannels/ -- NEWS: Paragon BioTeck, Inc., a privately held biopharmaceutical and medical device company specializing in the development of ophthalmic pharmaceuticals, devices and therapies, announces that it will be formally launching its corporate citizenship initiative coined, Paragon Gives. On Sunday October 19, 2014, Paragon BioTeck, will kick off its newly branded corporate social responsibility initiative at the annual American Academy of Ophthalmology conference in Chicago.
Paragon BioTeck Receives 510(k) clearance from the Food and Drug Administration for its Comfortear Lacrisolve Absorbable Punctum Plug
PORTLAND, Ore. /eNewsChannels/ -- NEWS: Oregon's Paragon BioTeck, Inc., a privately held biopharmaceutical and medical device company specializing in the development of ophthalmic pharmaceuticals, devices and therapies, announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Comfortear(R) Lacrisolve(TM) Absorbable Punctum Plug.
